Study to Assess Bioavailability of GLPG1690 Given as Oral Capsule or Tablet

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE1

Total Enrollment

12 participants

Study Classification

INTERVENTIONAL

Study Start Date

2017-04-18

Study Completion Date

2017-06-14

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study is a Phase I, randomized, open-label, cross-over study with three single-dose treatments to compare the bioavailability of an oral tablet relative to an oral capsule of GLPG1690 after single dose intake in healthy male subjects and to evaluate the effect of food on the bioavailability of the oral tablet.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Study to Compare Bioavailability of GLPG1972 Given as 2 Different Tablet Formulations Versus an Oral Solution

NCT03143725

Healthy

COMPLETED PHASE1

Oral Bioavailability of Two Solid Formulations of GLPG0634

NCT01915667

Healthy

COMPLETED PHASE1

A Study in Healthy Volunteers to Compare Different Tablet Formulations of the Test Medicine, GLPG1972, Against the Current Tablet Formulation, and to Assess the Effect Food Has on One of the Test Medicines

NCT04137341

Healthy

COMPLETED PHASE1

GLPG0259 Solid Formulation Bioavailability and Food Effect

NCT01024517

Healthy

COMPLETED PHASE1

Bioavailability Study of Prodrug of GLPG0187 in Healthy Volunteers

NCT01580644

Healthy

COMPLETED PHASE1

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Healthy

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

CROSSOVER

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Treatment A

GLPG1690 oral capsules after breakfast

Group Type EXPERIMENTAL

GLPG1690

Intervention Type DRUG

Oral administration of GLPG1690 in three different treatment conditions (treatment A through C)

Treatment B

GLPG1690 oral tablets after breakfast

Group Type EXPERIMENTAL

GLPG1690

Intervention Type DRUG

Oral administration of GLPG1690 in three different treatment conditions (treatment A through C)

Treatment C

GLPG1690 oral tablets after overnight fast

Group Type EXPERIMENTAL

GLPG1690

Intervention Type DRUG

Oral administration of GLPG1690 in three different treatment conditions (treatment A through C)

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

GLPG1690

Oral administration of GLPG1690 in three different treatment conditions (treatment A through C)

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Male between 18-50 years of age, inclusive
2. Body mass index (BMI) between 18-30 kg/m2, inclusive, with a weight of at least 50 kg.
3. Judged by the investigator to be in good health based upon the results of a medical history, physical examination, vital signs, 12-lead ECG, and laboratory findings.
4. Discontinuation of all medications except occasional paracetamol at least 2 weeks or 5 half-lives prior to the first study drug administration
5. Non-smokers and not using any nicotine-containing products.
6. Negative urine drug screen and alcohol breath test.
7. Current sexually active male agrees to use adequate contraception/preventive exposure measures from the time of first dose of study drug, during the study and until 12 weeks after the last study drug dose.
8. Subjects should be willing to consume the non-vegetarian high-fat and high-calorie breakfast.
9. Able and willing to sign the ICF

Exclusion Criteria

1. Known hypersensitivity to study drug ingredients or a significant allergic reaction to any drug
2. Positive serology for hepatitis B virus surface antigen (HBsAg) or hepatitis C virus (HCV) or any history of hepatitis from any cause with the exception of hepatitis A.
3. History of or a current immunosuppressive condition.
4. Presence of abnormal liver function. Diagnosis of disease of Gilbert is accepted. Retesting is allowed.
5. Renal function with an estimated creatinine clearance \<80 ml/min based on the Cockcroft-Gault formula. Retesting is allowed.
6. Presence of any condition known to interfere with absorption, distribution, metabolism or excretion of drugs.
7. History of malignancy within the past 5 years
8. Clinically relevant abnormalities detected on ECG regarding either rhythm or conduction (e.g., QTcF \>450 ms, or a known long QT syndrome).
9. Clinically relevant abnormalities detected on vital signs.
10. Dietary requirements precluding participation in the study
11. Significant blood loss (including blood donation \[≥450 mL\]), or transfusion of any blood product within 8 weeks prior to the signing of ICF.
12. Active drug or alcohol abuse within 2 years prior to the initial study drug administration.
13. Consumption of large quantities of caffeinated coffee or tea (\>6 cups/day), or equivalent.
14. Concurrent participation or participation in a drug or drug/device investigational research study.
15. Subjects who participated in a previous study with the same compound (GLPG1690).
16. Investigator or any sub-investigator, or other staff or relative.
17. Any condition or circumstances that in the opinion of the investigator may make a subject unlikely or unable to complete the study or comply with study procedures and requirements.

Minimum Eligible Age

18 Years

Maximum Eligible Age

50 Years

Eligible Sex

MALE

Accepts Healthy Volunteers

Yes